ClinicalTrials.gg
CompletedNCT06911242Updated May 1, 2026Results posted

A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions

A Phase 1 interventional study of ARN-75039 in Healthy Volunteer and Pharmacokinetics After Oral Intake, sponsored by Arisan Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Arisan Therapeutics, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

ARN-75039-103 is a comparative, randomized, single-dose, cross-over study to assess the PK, safety, and tolerability of neat ARN-75039 in hydroxypropyl methylcellulose (HPMC) capsules compared with ARN-75039 with excipients in tablet form, both administered orally, in healthy adult participants. The safety assessments will include standard evaluations of vital signs, clinical laboratory values, and ECGs.

Participants will be admitted to the study site on the morning of Day -1, before Period 1 study drug administration, and will remain on site until Day 15. Upon confirmation of eligibility, participants will be randomized into the study on Day 1. Study drug administration will be performed on the first day of Periods 1 and 2 (Study Days 1 and 8, respectively) with a 7-day washout period between the two periods. Participants will receive the randomized study drug in the morning following a meal. A total of 16 participants will be randomized 1:1 to the following two sequences:

  • Sequence 1:

    • Form A: Neat ARN-75039 in HPMC capsules (reference product)
    • Form B: ARN-75039 with excipients in tablet form (comparator)
  • Sequence 2:

    • Form B: ARN-75039 with excipients in tablet form (comparator)
    • Form A: Neat ARN-75039 in HPMC capsules (reference product)

Participation in the study will be conducted in the following 5 defined periods:

  • Screening Period: The Screening Period begins upon completion of the informed consent form (ICF). During this period, participants will undergo baseline assessments to determine eligibility for study participation. The Screening Period duration will be up to 21 days; it will end after all evaluations required to meet eligibility have been completed. If a participant meets all eligibility criteria, they will be offered enrollment into the study.
  • Admission to Study Site: Participants will be admitted to the study site in the morning on the day before dosing of period 1 (Day -1). Participants who are eligible to participate in the study and are randomized into the study will remain at the study site until completion of the treatment period (Study Day 15).
  • Treatment Period: This study consists of two treatment days separated by a 7-day washout period. The first treatment day will begin on Day 1 of Period 1 with administration of the first dose of study drug. The second treatment day will occur on the first day of Period 2 (Study Day 8). Following the dosing of the study drug on each treatment day, fifteen venous blood samples will be withdrawn via an indwelling cannula or by venipuncture at regular time intervals.
  • End of Active Treatment (Day 15 Discharge Visit or Early Termination (ET) Visit): Upon successful completion of active treatment, participants will be discharged from the study site on Study Day 15. The Discharge Visit will include the completion of safety assessments, such as a physical examination, vitals, ECG recording, adverse event review, and clinical laboratory tests. Participants who complete both dosing days will be encouraged to complete all study visits.

Participants who do not complete all study visits or terminate from the study before Day 15 will be asked to complete The Early Termination Visit is within 1 day after withdrawal from the study.

  • Day 36 Telephone Follow-Up Phone Call: Participants will be contacted by phone on Day 36-i.e., 28 days following the last study dose administered on Day 8. The purpose of this follow-up call is to assess for any adverse events.
Read the detailed description

Two-period cross-over, Form A vs Form B, fed, inpatient Day -1 through Day 15, Day 36 follow-up

02

Conditions studied

  • Healthy Volunteer
  • Pharmacokinetics After Oral Intake

Keywords

  • Pharmacokinetics
  • Relative Bioavailability
  • Crossover
  • ARN-75039
  • HPMC capsule
  • Tablet With Excipients
03

In context

Lead sponsor

Arisan Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants meeting all the following criteria are eligible for study participation:

  1. Is male or female, age 18 to 45 years, inclusive, at Screening.
  2. (BMI) between 18 and 35 kg/m2, inclusive, at Screening.
  3. In good general health, determined by no findings in the opinion of the Investigator from medical history, physical examination, 12-lead , clinical laboratory findings, and vital signs at Screening and Day -1 or 1.
  4. , hematocrit, white blood cell count, , and count results within the laboratory reference range at Screening or without clinically significant abnormalities in the opinion of the Investigator; participants with Gilbert's disease with associated abnormalities of liver function tests are eligible for enrollment. Tests may be repeated at the discretion of the Investigator to confirm abnormalities.
  5. Estimated (eGFR) based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of ≥ 80 mL/min/1.73 m2 at Screening.
  6. Females of must practice effective per national regulatory guidelines for clinical trials from Screening (see Section 5.6.2), throughout the study, and for 60 days after the last dose of study drug.
  7. Females must have a negative pregnancy test at Screening and within 24 hours prior to dosing of study drug; for participants, a blood sample will also be tested for estradiol and follicle stimulating hormone (FSH) to confirm post-menopausal status based on reference laboratory ranges for post-menopausal status. Surgically sterile females are eligible; however, proof via medical records will be required.
  8. Males must agree to not donate sperm and to use condom and spermicide in combination with any of the means of contraception for their female partners during sexual intercourse from the time of the first study drug administration and for 90 days following the last dose of study drug. Females must agree not to donate eggs from the time of the first study drug administration and for 60 days following the last dose of study drug.
  9. Must be willing and able to comply with measures to avoid photosensitivity reactions (i.e., avoidance of outdoor sun exposure and tanning; consistent use of long sleeve shirts, long pants, hats, and sunglasses; consistent use of sun protection factor [SPF] 75 or greater sunscreen when outdoors) during the study treatment period.
  10. Able to consume a standard meal (400-600 Calories) within 30 minutes.
  11. Able to provide .
  12. Willing and able to comply with this protocol and be available for the entire duration of the study.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for study participation:

  1. Any underlying illness in the opinion of the Investigator.
  2. Poor venous access.
  3. Prior exposure to ARN-75039.
  4. History of drug or alcohol abuse within 1 year of Screening in the opinion of the investigator, or a positive test for drugs of abuse or alcohol at Screening or Day -1.
  5. Use of any prescription or over-the-counter (OTC) medications, including food supplements, vitamins, herbal medications (e.g., St. John's wort), and cannabis, with the exception of medications and as needed (prn) acetaminophen or paracetamol (not exceeding 2 grams/day) within 7 days prior to study drug administration and through the Day 15 Discharge visit.
  6. Any female who is pregnant or breastfeeding, or any female who is planning to become pregnant during the study and safety follow-up period.
  7. Currently enrolled in another device or drug study, or less than 30 days or 5 half-lives of the prior investigational agent (whichever is longer) or plans to enroll in another investigational device or drug study during the course of this study.
  8. Inability to ingest all capsules/tablets of a multi-capsule dose within 5 minutes of ingestion of the first capsule/tablet.
  9. Positive serology for virus (HBV), virus (HCV), or (HIV) at Screening; participants with adequately treated HCV are eligible for enrollment.
  10. Consumption of Seville oranges, grapefruit or grapefruit juice within 72 hours prior to Day 1 or during the study.
  11. History of , except adequately treated basal cell carcinoma or in situ carcinoma of the uterine cervix.
  12. Smoking cigarettes, cigars, cigarillos or E-cigarettes
  13. Any reason or condition that, in the investigator's opinion, may compromise study participation, present a safety risk to the participant, or may confound the interpretation of the study results.
  14. A duration corrected for heart rate by Fridericia's formula (QTcF) > 450 millisecond (msec) based on either single or averaged QTcF values of triplicate ECGs obtained over a 3-minute interval (at Screening).
  15. Blood product (including plasma) donation within 30 days before Screening.
  16. Unwilling to consume a breakfast on study drug administration days.
  17. History of:

    • Structural abnormality of the GI tract or a disease or history of a condition that can affect GI motility.
    • Inflammatory bowel disease (even if treated and currently in remission).
    • Diverticulitis or any other chronic condition such as chronic pancreatitis, polycystic kidney disease, ovarian cysts, endometriosis, lactose intolerance that can be associated with abdominal pain or discomfort and could confound the assessments in this trial.
    • Chronic idiopathic diarrhea.
  18. Formally diagnosed colonic inertia or conditions that can be associated with constipation: pseudo-obstruction, colonic inertia, megacolon, megarectum, bowel obstruction, descending perineum syndrome, solitary rectal ulcer syndrome, systemic sclerosis, lower tract evacuation disorders, functional outlet delay (e.g., rectal prolapse, anismus, etc.).
  19. Current active peptic ulcer disease (i.e., disease that is not adequately treated or stable with therapy.)
  20. Potential central nervous system cause of constipation (e.g., Parkinson's disease, spinal cord injury, and multiple sclerosis).
  21. Participant currently has both unexplained and clinically significant alarm symptoms (lower GI bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia or any unexplained anemia, or weight loss) or systemic signs of infection or colitis.
  22. History of chronic/generalized pruritus and/or skin rash of unknown origins.
  23. Participants with diagnosed Type 1 or Type 2 diabetes, or with a fasting blood glucose value > 125 mg/dL during the screening period.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Form A

    Investigational antiviral agent (300 mg neat ARN-75039 in HPMC capsules) administered as a single oral dose for pharmacokinetic evaluation.

    Drug: ARN-75039

  • Experimental
    Form B

    Investigational antiviral agent (3x100 mg ARN-75039 tablet with excipients) administered as a single oral dose for pharmacokinetic evaluation.

    Drug: ARN-75039

Interventions

  • An oral therapy for the treatment of Lassa infection

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area Under the Plasma-drug Concentration Time Curve from time zero to time of last quantifiable concentration. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.

    Time frame: From time zero (dose) to time of last quantifiable concentration. Period 1: 0 to 144 hours; Period 2: 0 to 168 hours.

  2. AUC0-24

    Area under the plasma concentration-time curve from time zero to 24 hours post-dose. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.

    Time frame: From time zero (dose) to 24 hours post-dose.

  3. AUC0-∞

    Area under plasma concentration-time curve from time zero to infinity. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.

    Time frame: From time zero (dose) extrapolated to infinity. Time frame is from 0 to Tlast + extrapolation from C last to infinity time, where concentration is equal to 0.

  4. Cmax

    Maximum observed plasma concentration. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.

    Time frame: From time 0 (dose) through 168 hours post-dose.

  5. Tmax

    Time to reach Cmax

    Time frame: From time 0 (dose) through 168 hours post-dose.

  6. t1/2

    Half-life

    Time frame: From time 0 (dose) through 168 hours post-dose (terminal elimination phase).

  7. CL/F

    Apparent clearance after extravascular administration.

    Time frame: From time 0 (dose) through 168 hours post-dose (derived from the concentration-time profile).

  8. Vz/F

    Apparent volume of distribution during the terminal phase after extravascular administration.

    Time frame: From time 0 (dose) through 168 hours post-dose (derived from the concentration-time profile).

Secondary outcomes

  1. Participants With ≥1 TEAE

    Type and frequency of treatment-emergent adverse events (TEAEs).

    Time frame: From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).

  2. Participants With ≥1 TESAE

    Type and frequency of treatment-emergent serious adverse events (TESAEs).

    Time frame: From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).

  3. Participants With Study Drug-related TEAEs of Grade >1

    Type and frequency of study drug-related \>Grade 1 TEAEs

    Time frame: From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).

07

Results

Posted May 1, 2026
Limitations and caveats
The study is a Phase 1 (N=16) trial and is not powered for efficacy. AUC0-∞, CL/F, and Vz/F had fewer analyses due to insufficient terminal sampling; AUC0-∞ was excluded from BE testing per SAP.

Participant flow

Sixteen participants were enrolled, and none discontinued the study early or were excluded from analysis. All the informed consent forms (ICFs) were signed within the window from February 27, 2025 and March 11, 2025.

First Intervention (day 1)
Participant flow — First Intervention (day 1)
MilestoneSequence 1: Form A (Capsule), Then Form B (Tablet)Sequence 2: Form B (Tablet), Then Form A (Capsule)
Started88
Completed88
Not completed00
Washout (days 2 - 7)
Participant flow — Washout (days 2 - 7)
MilestoneSequence 1: Form A (Capsule), Then Form B (Tablet)Sequence 2: Form B (Tablet), Then Form A (Capsule)
Started88
Completed88
Not completed00
Second Intervention (day 8)
Participant flow — Second Intervention (day 8)
MilestoneSequence 1: Form A (Capsule), Then Form B (Tablet)Sequence 2: Form B (Tablet), Then Form A (Capsule)
Started88
Completed88
Not completed00

Outcome measures

PrimaryAUC0-t

Area Under the Plasma-drug Concentration Time Curve from time zero to time of last quantifiable concentration. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.

Time frame:
From time zero (dose) to time of last quantifiable concentration. Period 1: 0 to 144 hours; Period 2: 0 to 168 hours.
Reported as:
Mean · h*ng/ml
AUC0-t
h*ng/mlARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
AUC0-t9450 ± 32308990 ± 3060
PrimaryAUC0-24

Area under the plasma concentration-time curve from time zero to 24 hours post-dose. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.

Time frame:
From time zero (dose) to 24 hours post-dose.
Reported as:
Mean · h*ng/ml
AUC0-24
h*ng/mlARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
AUC0-246150 ± 21205820 ± 1980
PrimaryAUC0-∞

Area under plasma concentration-time curve from time zero to infinity. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.

Time frame:
From time zero (dose) extrapolated to infinity. Time frame is from 0 to Tlast + extrapolation from C last to infinity time, where concentration is equal to 0.
Reported as:
Mean · h*ng/ml
AUC0-∞
h*ng/mlARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
AUC0-∞11800 ± 25709700 ± 2770
PrimaryCmax

Maximum observed plasma concentration. Compare the pharmacokinetic (PK) properties of 300mg ARN-75039 with excipients in tablet form to 300mg neat ARN-75039 in HPMC capsules following oral administration under fed conditions.

Time frame:
From time 0 (dose) through 168 hours post-dose.
Reported as:
Mean · ng/ml
Cmax
ng/mlARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
Cmax847 ± 266828 ± 226
PrimaryTmax

Time to reach Cmax

Time frame:
From time 0 (dose) through 168 hours post-dose.
Reported as:
Median · h
Tmax
hARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
Tmax4 ± 2-63.5 ± 2-4.1
Primaryt1/2

Half-life

Time frame:
From time 0 (dose) through 168 hours post-dose (terminal elimination phase).
Reported as:
Mean · h
t1/2
hARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
t1/2141 ± 52.4120 ± 49.1
PrimaryCL/F

Apparent clearance after extravascular administration.

Time frame:
From time 0 (dose) through 168 hours post-dose (derived from the concentration-time profile).
Reported as:
Mean · L/h
CL/F
L/hARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
CL/F26.4 ± 5.9935 ± 17.1
PrimaryVz/F

Apparent volume of distribution during the terminal phase after extravascular administration.

Time frame:
From time 0 (dose) through 168 hours post-dose (derived from the concentration-time profile).
Reported as:
Mean · L
Vz/F
LARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
Vz/F3820 ± 12904810 ± 2270
SecondaryParticipants With ≥1 TEAE

Type and frequency of treatment-emergent adverse events (TEAEs).

Time frame:
From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).
Reported as:
Number · Participant count
Participants With ≥1 TEAE
Participant countARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
Participants With ≥1 TEAE03
SecondaryParticipants With ≥1 TESAE

Type and frequency of treatment-emergent serious adverse events (TESAEs).

Time frame:
From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).
Reported as:
Number · Participant count
Participants With ≥1 TESAE
Participant countARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
Participants With ≥1 TESAE00
SecondaryParticipants With Study Drug-related TEAEs of Grade >1

Type and frequency of study drug-related \>Grade 1 TEAEs

Time frame:
From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs).
Reported as:
Number · Participant count
Participants With Study Drug-related TEAEs of Grade >1
Participant countARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
Participants With Study Drug-related TEAEs of Grade >100

Adverse events

Collected over From first dose through approximately 7 days after the last dose (includes washout); with Day 36 follow-up phone call to assess for any adverse events (AEs). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARN-75039 Form A (HPMC Capsule)0/16 (0%)0/16 (0%)0/16 (0%)
ARN-75039 Form B (Tablet With Excipients)0/16 (0%)0/16 (0%)3/16 (18.8%)
Most frequent other events
Most frequent other events
EventARN-75039 Form A (HPMC Capsule)ARN-75039 Form B (Tablet With Excipients)
Sinus tachycardiaCardiac disorders0/161/16
HeadacheNervous system disorders0/161/16
Rash macularSkin and subcutaneous tissue disorders0/161/16

Baseline characteristics

Safety/PK population: all randomized participants who received at least 1 dose of study drug. In the cross-over design, results are presented per intervention (Form A vs Form B) by pooling all participants exposed to each intervention across periods/sequences; participants contribute data to both arms. Events are attributed to the treatment received at onset; events during washout are attributed to the prior treatment.

Age, Continuous
Age, Continuous(years)All Participants
Mean37.7 ± 5.96
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female7
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American7
White9
More than one race0
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino12
Not Hispanic or Latino4
Unknown or Not Reported0
Weight
Weight(kg)All Participants
Mean74.1 ± 9.96
Height
Height(cm)All Participants
Mean167.8 ± 7.48
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)All Participants
Mean26.4 ± 3.61
08

Study locations

1 site
  • Frontage
    Secaucus, New Jersey 07094, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Apr 2025, 1 month.

Results were first posted in May 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Apr 4, 2025
StartActual
Feb 27, 2025
Primary completionActual
Apr 21, 2025
CompletionActual
Apr 21, 2025
Results first posted
May 1, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06911242
Lead sponsor
Arisan Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Feb 27, 2025
Primary completion
Apr 21, 2025
Completion
Apr 21, 2025
Results posted
May 1, 2026
Last update
May 1, 2026

Study contacts

Ken McCormack, PhD
study chair · Arisan Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARN-75039

Start the discussion